Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.67) by 47.76 percent. This is a 40.68 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $32.98 million which beat the analyst consensus estimate of $9.38 million by 251.72 percent. This is a 479.03 percent increase over sales of $5.70 million the same period last year.